ITGAM and neoplasm: The identification of particular subpopulations of MDSCs was performed according to the procedure outlined in Figure 4E. Generally, after treatment with LVs (either with shN or shTGFβ1-1), the numbers of PMN-MDSC constituted approximately 2% of all CD11b+ cells in tumor and were significantly lower than in the MC38 control (10%; Figure 4F).